Get a reply from this employer — a resume and cover letter tailored to exactly what they’re hiring for.
Replimune is seeking a Quality Assurance Officer I to guide and coordinate QA systems for drug product release at our Milton Park site. The role ensures GMP compliance and regulatory alignment with MHRA, EMA, and FDA requirements, with a 5-day on-site expectation.
You will work cross-functionally to support batch release, CAPA, deviations, and quality metrics, contributing to a robust QA program across vendors and internal teams.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because patient’s lives depend on it.
At Replimune, we live by our values:
United: We Collaborate for a Common Goal.
Audacious: We Are Bold.
Dedicated: We Give Our Full Commitment.
Candid: We Are Honest With Each Other.
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward‑looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
The Quality Assurance Officer I provides guidance and coordination in the development, implementation and maintenance of Quality Assurance systems and activities at Replimune. Manages batch review to ensure timely release of drug product for clinical and commercial use. Ensures relevant quality and regulatory requirements are met for manufacturing and testing and ensures site compliance with quality system regulations issued by MHRA, EMA, FDA and other applicable regulatory bodies. Responsible for the evaluation and assurance that appropriate quality systems are in place at approved vendors and suppliers supporting GXP.
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus‑mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.